- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01434810
Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Numerous studies from resource-limited countries suggest that severe neonatal jaundice (NNJ) represents the largest unrecognized cause of neonatal morbidity and mortality in the world. Several studies from Africa rank jaundice as a leading cause of death in newborn nurseries. In Nigeria, Owa and Osinaike reported that jaundice (14%) was the second leading cause of death, while Ugwu et al, found that mortality from severe jaundice was comparable to birth asphyxia but greater than sepsis in neonates >24 hrs old to 7 days old. In Kenya, English et al reported NNJ as the third leading cause of both newborn admissions and deaths. Studies from Nigeria, Zimbabwe, Turkey, North Vietnam, Oman, and India listed acute bilirubin encephalopathy (ABE) and/or severe NNJ as a significant cause of morbidity, many of whom required exchange blood transfusion (EBT) in their nurseries. Unfortunately, phototherapy, as important as it is, may not be available to many infants with NNJ in these countries because of the lack of devices and/or of unreliable electrical power supply. Commercial phototherapy (PT) devices are expensive, often break down due to surges in electrical power, and are difficult to maintain due to unavailability of spare parts. Even where PT devices are available, most hospitals in these countries lack the resources to replace the fluorescent light bulbs at the recommended 2000-3000 hrs of use and simply leave ineffective tubes in place until they burn out. Moreover, very few hospitals have appropriate irradiance meters for monitoring the intensity of the blue light emitted by the lamps. In a recent study in Nigeria by Owa et al, none of the tested PT devices provided the level of irradiance required for intensive PT.
Often, the only treatment a healthcare provider can suggest to the parents/guardians of jaundiced infants is to place their babies in sunlight. However, this practice is unsuitable due to several safety concerns. For instance, exposure to ultraviolet (UV) light may cause sunburn, while infrared (IR) light may cause the body to overheat. Moreover, the infant may lose body heat from the uncovered skin during treatment, with potential for dehydration. A safer, yet practical and economical, solution is needed, providing the basis for our proposal of filtered sunlight PT.
The primary aims of this study were safety, efficacy and non-inferiority of filtered sunlight phototherapy compared to conventional phototherapy. Phase I of the study focused on the safety and efficacy of filtered sunlight phototherapy. Phase II focused on non-inferiority of efficacy as compared to conventional phototherapy while continuing to evaluate safety.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lagos, Nigeria
- Island Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be eligible to participate in the study if all of the following conditions exist:
- At time of birth, infant is > 35 weeks gestation (or > 2.2 kg if gestational age is not available
- Infant is < 14 days old at the time of enrollment
- At time of enrollment, infant has an elevated TcB defined as 3 mg/dL below the level recommended for high-risk infants per AAP guidelines or higher
- Parent or guardian has given consent for the infant to participate
Exclusion Criteria:
Subjects will be excluded from participation in the study if any of the following conditions exist at the time of enrollment:
- Infants with a condition requiring referral for treatment not available at the hospital study site and/or conventional phototherapy unit.
- Infants with a life-expectancy of < 24 hours
- Infants requiring oxygen therapy
- Infants clinically dehydrated or sunburned
- Infants with a temperature < 35.5 or > 38 degrees Centigrade
- Infants with ABE on clinical exam
- Infants meeting the criteria for EBT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Filtered-sunlight phototherapy
Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days.
The filtering will be done using window tinting film.
Window tinting films by Solutia, Inc., and V-KOOL, Inc.
|
Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days.
The filtering will be done using window tinting film.
Window tinting films by Solutia, Inc., and V-KOOL, Inc.
|
Active Comparator: Conventional phototherapy
Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
|
Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Phototherapy
Time Frame: Four to ten days
|
For a given treatment day, the phototherapy treatment was deemed safe if that infant on that day did not have to be withdrawn from treatment due to hypo- or hyperthermia, sunburn or dehydration.
Therefore safety is reported as a percentage of the total treatment days (i.e.
number of safe treatment days divided by total number of treatment days).
|
Four to ten days
|
Efficacy of Phototherapy
Time Frame: Four to ten days
|
For a given evaluable treatment day, the phototherapy treatment was deemed effective if that infant on that day had a decrease in serum bilirubin level or (if <72hrs old) an rate of increase of less than 0.2 mg/dL/h.
Therefore efficacy is reported as a percentage of the evaluable treatment days (i.e.
number of effective evaluable treatment days divided by total number of evaluable treatment days).
|
Four to ten days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Requiring Exchange Blood Transfusion
Time Frame: Four to ten days
|
Exchange blood transfusion required to lower the bilirubin level.
Serum bilirubin will be measured twice daily during filtered sunlight or conventional phototherapy exposure, for an expected average of four days, and a maximum of ten days.
|
Four to ten days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tina M Slusher, MD, University of Minnesota
Publications and helpful links
General Publications
- Slusher TM, Olusanya BO, Vreman HJ, Brearley AM, Vaucher YE, Lund TC, Wong RJ, Emokpae AA, Stevenson DK. A Randomized Trial of Phototherapy with Filtered Sunlight in African Neonates. N Engl J Med. 2015 Sep 17;373(12):1115-24. doi: 10.1056/NEJMoa1501074.
- Slusher TM, Olusanya BO, Vreman HJ, Wong RJ, Brearley AM, Vaucher YE, Stevenson DK. Treatment of neonatal jaundice with filtered sunlight in Nigerian neonates: study protocol of a non-inferiority, randomized controlled trial. Trials. 2013 Dec 28;14:446. doi: 10.1186/1745-6215-14-446.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1108M03601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Jaundice, Neonatal
-
Muhammad ZarkNot yet recruitingPhysiological Neonatal Jaundice | Physiological HyperbilirubinaemiaPakistan
-
Ege UniversityAssociate Professor Figen YARDIMCINot yet recruitingUnspecified Fetal and Neonatal Jaundice
-
University of AarhusCompletedUncomplicated Neonatal HyperbilirubinemiaDenmark
-
Guangzhou Women and Children's Medical CenterRecruitingNeonatal Hyperbilirubinemia | Neonatal Jaundice | Hemolysis NeonatalChina
-
Guizhou Provincial People's HospitalRecruiting
-
University Hospital, LilleInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingNeonatal JaundiceFrance
-
Picterus ASNorwegian University of Science and TechnologyTerminatedNeonatal JaundiceUganda
-
University of MinnesotaHennepin Healthcare Research InstituteCompleted
-
National Liver Institute, EgyptCompleted
-
Picterus ASIntermountain Medical CenterRecruitingNeonatal JaundiceUnited States
Clinical Trials on Filtered-sunlight phototherapy
-
University of MinnesotaThrasher Research FundCompletedFiltered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates (FSPT)Jaundice, NeonatalNigeria
-
Taipei Veterans General Hospital, TaiwanCompletedDepression | StrokeTaiwan
-
Chiayi Christian HospitalNational Cheng Kung UniversityUnknownQuality of Life | Cognitive Impairment | Aging | Depression in Old Age | Nursing HomesTaiwan
-
UConn HealthNational Institute on Drug Abuse (NIDA)Recruiting
-
The Hospital for Sick ChildrenWithdrawn
-
Robert Tighe, MDCompletedEnvironmental and Genetic Factors on Lung FunctionUnited States
-
University of Nove de JulhoCompletedPhotobiomodulation In the Masseter and Temporal In Patients With Temporomandibular Joint DysfunctionTemporomandibular Disorder
-
University of ZurichCompletedPsoriasis | EczemaSwitzerland
-
Robert Tighe, MDNational Institutes of Health (NIH); Ohio State UniversityCompletedHealthyUnited States
-
Umeå UniversityKing's College LondonCompleted